DSP Healthcare Fund emerged as the top-performing sectoral fund in the pharma category over the past three months, delivering a 22.2% return. While the fund has outperformed its benchmark consistently over one and three-year periods, investors should note that sector funds carry higher risks due to their narrow focus on a single industry.
The DSP Healthcare Fund has outperformed its peers in the pharmaceutical and healthcare sectoral mutual fund category, recording a 22.2% return over the last three months. Data as of July 6, 2026, positions it ahead of other prominent funds in the space, including the SBI Healthcare Opportunities Fund, which posted a 21.7% return, and the Mirae Asset Healthcare Fund, which saw a 19.0% gain during the same period.
Benchmark Comparison and Performance
Beyond short-term results, the fund has demonstrated significant outperformance against its benchmark index over longer timeframes. On a one-year basis, the fund outperformed the benchmark by 13.9 percentage points, a notable result considering the benchmark itself returned -2.9% during the period. Similarly, over a three-year horizon, the fund maintained a lead of 13.2 percentage points over the benchmark, which posted a 9.1% return. This indicates a period of effective fund management, though performance trends often fluctuate based on broader healthcare sector cycles.
Sector Volatility and Portfolio Concentration
Performance leadership among healthcare funds often shifts depending on the observation period. For example, while the DSP Healthcare Fund leads the three-month window, the SBI Healthcare Opportunities Fund held the top position over the six-month period with a 16.5% return. Meanwhile, the Mirae Asset Healthcare Fund outperformed peers over a one-year window, delivering a 14.2% gain. These variations highlight the inherent volatility of sector-specific investing, where a fund's success is tied heavily to the specific performance of pharmaceutical and healthcare companies.
Investors considering these funds should note that they are not as diversified as broad equity funds. The Nippon India Pharma Fund, for instance, remains the largest in this group with assets under management totaling Rs 8,635.7 crore. Because these funds concentrate capital within a single industry, they are more sensitive to sector-specific risks, such as changes in drug pricing regulations, global export demand, or raw material cost pressures. Investors may monitor how these funds rebalance their portfolios in response to changing sector conditions rather than relying solely on past short-term return data.